Bildkälla: Stockfoto

Idogen Q2’21: Approaching Clinic - Redeye

Redeye leaves a comment on Idogen following the report for the second quarter of 2021. The most central aspect for the company is tied to the preparations of IDO 8 for clinical studies.

Redeye leaves a comment on Idogen following the report for the second quarter of 2021. The most central aspect for the company is tied to the preparations of IDO 8 for clinical studies.
Börsvärldens nyhetsbrev
ANNONSER